Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $270.48M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.69M
Average 3.81M
ALT Total Current Liabilities
All obligations due within one year.
Altimmune, Inc.NASDAQ: ALT
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 15.6% from a year ago
Total current liabilities stood at $11.32M at the end of Q1 FY2026, up 15.6% from a year earlier and down 24.5% from the prior quarter. Over 3 fiscal years it compounded at -4.2% a year.
Context
- Total current liabilities amounted to 3.4% of total assets at the end of Q1 FY2026, down 2.9 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +15.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 15M USD
- Year-over-year change
- +43.3%
- 4-year CAGR
- -4.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15M | +43.3% |
| FY2024 | 2024-12-31 | 10.47M | -13.8% |
| FY2023 | 2023-12-31 | 12.14M | -28.8% |
| FY2022 | 2022-12-31 | 17.05M | -6.7% |
| FY2021 | 2021-12-31 | 18.28M | — |
Total Current Liabilities vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +15.6% is the 2nd highest of 9, against a peer median of -41.2%.
- Total current liabilities amounts to 3.4% of total assets for ALT, versus a peer median of 14.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €77.35M EUR | -35.9% | +36.1% | 31.1% | |
| Mar 2026 | $73.56M USD | -46.4% | -43.4% | 7.2% | |
| Jun 2026 | $66.11M USD | +69.4% | +69.4% | 4.6% | |
| Mar 2026 | $46.44M USD | +1.1% | +17.6% | 14.8% | |
| Mar 2026 | $35M USD | -24.9% | +44.1% | 14.9% | |
| Mar 2026 | $11.32M USD | +15.6% | -4.2% | 3.4% | |
| Mar 2026 | $9.29M USD | -53.1% | -16.5% | 20.0% | |
| Mar 2026 | $5.11M USD | -73.7% | -43.2% | 1.8% | |
| Mar 2026 | $933K USD | -64.3% | +21.5% | 42.8% | |
| Peer median (excluding ALT) | — | -41.2% | +19.6% | 14.8% | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 190.3M | 111.1M | 135.12M | 36.93M | 43.76M |
| Short-term Investments | 0 | 73.78M | 62.7M | 94.97M | 229.7M |
| Net Receivables | 5.84M | 2.54M | 4.85M | 3.12M | 1.74M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 33.31K | 5.39M | 6.96M | 2.25M | 3M |
| Total Current Assets | 204.13M | 192.81M | 209.63M | 137.25M | 278.19M |
| Property, Plant & Equipment (Net) | 1.45M | 1.08M | 651K | 413K | 312K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 12.42M | 12.42M | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 872K | 615K | 363K | 1.64M | 1.43M |
| Total Non-current Assets | 14.74M | 14.12M | 1.01M | 2.05M | 1.74M |
| Total Assets | 218.87M | 206.93M | 210.64M | 139.31M | 279.93M |
| Account Payables | 2.03M | 4.8M | 2.07M | 211K | 2.72M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 1.17M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.09M | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 18.28M | 17.05M | 12.14M | 10.47M | 15M |
| Long-term Debt | 0 | 0 | 0 | 0 | 34.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 160K |
| Other Non-current Liabilities | 330K | 3.91M | 4.22M | 3.93M | 4.45M |
| Total Non-current Liabilities | 1.45M | 4.58M | 4.4M | 5.33M | 40.04M |
| Total Liabilities | 19.73M | 21.64M | 16.54M | 15.8M | 55.04M |
| Common Stock | 4K | 5K | 7K | 7K | 11K |
| Retained Earnings | (293.17M) | (377.88M) | (466.33M) | (561.39M) | (649.48M) |
| Accumulated OCI | (5.04M) | (5.23M) | (5M) | (4.97M) | (4.93M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 199.14M | 185.29M | 194.1M | 123.51M | 224.89M |
| Total Debt | 1.54M | 1.12M | 671K | 1.68M | 35.69M |
| Net Debt | (188.77M) | (109.97M) | (134.45M) | (35.25M) | (8.07M) |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.